Medi Assist Healthcare Services Limited (NSE:MEDIASSIST) Just Reported Earnings, And Analysts Cut Their Target Price

Investors in Medi Assist Healthcare Services Limited (NSE:MEDIASSIST) had a good week, as its shares rose 5.9% to close at ₹468 following the release of its annual results. It was a workmanlike result, with revenues of ₹7.5b coming in 2.5% ahead of expectations, and statutory earnings per share of ₹12.85, in line with analyst appraisals. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Medi Assist Healthcare Services after the latest results.

We check all companies for important risks. See what we found for Medi Assist Healthcare Services in our free report.

Taking into account the latest results, the most recent consensus for Medi Assist Healthcare Services from three analysts is for revenues of ₹9.52b in 2026. If met, it would imply a substantial 27% increase on its revenue over the past 12 months. Per-share earnings are expected to accumulate 4.7% to ₹13.50. Before this earnings report, the analysts had been forecasting revenues of ₹9.96b and earnings per share (EPS) of ₹14.10 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the small dip in earnings per share expectations.

Check out our latest analysis for Medi Assist Healthcare Services

The consensus price target fell 9.1% to ₹630, with the weaker earnings outlook clearly leading valuation estimates. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Medi Assist Healthcare Services, with the most bullish analyst valuing it at ₹700 and the most bearish at ₹590 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Medi Assist Healthcare Services' rate of growth is expected to accelerate meaningfully, with the forecast 27% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 17% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Medi Assist Healthcare Services is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also downgraded Medi Assist Healthcare Services' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Medi Assist Healthcare Services going out to 2028, and you can see them free on our platform here.

We also provide an overview of the Medi Assist Healthcare Services Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.